Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01749306
Recruitment Status : Terminated
First Posted : December 13, 2012
Last Update Posted : November 21, 2013
Information provided by (Responsible Party):
Shire Regenerative Medicine, Inc.

Brief Summary:

The purpose of this study is to evaluate the efficacy and safety of ABH001 in the treatment of patients with epidermolysis bullosa who have wounds that are not healing.

It is hypothesized that ABH001 may initiate and continue wound healing in patients with epidermolysis bullosa.

Condition or disease Intervention/treatment Phase
Epidermolysis Bullosa Biological: ABH001 Other: Control wound treatment Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Prospective, Randomized, Open-label, Intra-subject Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated With Generalized Epidermolysis Bullosa
Study Start Date : December 2012
Actual Primary Completion Date : November 2013
Estimated Study Completion Date : November 2013

Arm Intervention/treatment
ABH001 application plus wound care dressings.
Biological: ABH001
ABH001 applications topically every 4 weeks (±1 week) with protocol-specified dressings until wound healed or up to 44 weeks
Other Name: Dermagraft, Allogenic Neonatal Dermal Fibroblasts Seeded on poly(glycolide-co-L-lactide) (PGLLA) Scaffold

Control wound treatment
Other: Control wound treatment
Control wound care with protocol-specified dressings every 4 weeks (±1 week) up to 20 weeks with optional cross-over to ABH001 for additional 20 weeks

Primary Outcome Measures :
  1. Reduction in wound surface area [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. Change in wound pain and wound itch [ Time Frame: 24 weeks ]
  2. Patient global impression of change (PGIC) [ Time Frame: 24 weeks ]
  3. Clinician global impression of change (CGIC) [ Time Frame: 24 weeks ]
  4. Proportion of subjects achieving reduction in wound surface area [ Time Frame: 24 weeks ]
  5. Time to reduction of wound surface area and duration of reduction [ Time Frame: 24 weeks ]
  6. Durability of wound healing [ Time Frame: 24 weeks ]
  7. Incidence, relatedness and severity of adverse events [ Time Frame: Up to 48 Weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The subject or legal guardian must have read, understood and signed an Institutional Review Board/Ethics Committee (IRB/EC) approved Informed Consent or Assent Form and must be able to and willing to follow study procedures and instructions
  2. Male and female subjects.
  3. Stable nutritional status.
  4. Subjects with a confirmed diagnosis of generalized Epidermolysis Bullosa (EB)
  5. Cutaneous wounds meeting the following criteria:

    1. Anatomical location: arms, legs, thorax, or back above the waistline and below the neck.
    2. Documented age (duration) of the wound(s).
    3. One or more wounds capable of potentially meeting the following wound selection criteria at the end of the observation period:

    i. Two clinically non-infected cutaneous wounds with no clinically meaningful change in wound size during the observation period.

    ii. Two matched wounds.

  6. Negative urine pregnancy test for women of child-bearing potential.
  7. Female subjects of childbearing potential and male subjects of procreative capacity must agree to use an effective method of contraception.

Exclusion Criteria:

  1. Pregnant or nursing women.
  2. Diagnosis of non-genetic generalized EB.
  3. Localized, active clinical infection of study wounds.
  4. Diseases or conditions that could interfere with the assessment of safety and efficacy of the study treatment and compliance of the subject with study visits/procedures.
  5. Known allergy to bovine products.
  6. Known allergy to silver products.
  7. Systemic infection at the time of enrolment in the study.
  8. Currently receiving or have received oral steroid therapy within the previous 4 weeks.
  9. Taking, or have participated in other clinical studies involving gene therapy, stem cell therapy, recombinant DNA/protein therapy.
  10. Received ABH001, or other biologic or cell therapy for the treatment of EB in the study wound sites within the previous 3 months.
  11. Hypersensitivity to any of the therapeutic agents.
  12. History of malignant skin disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01749306

Layout table for location information
United States, Arizona
Phoenix Children's Hospital
Phoenix, Arizona, United States
United States, California
Lucile Packard Children's Hospital at Stanford University
Redwood City, California, United States
Rady Children's Hospital - San Diego/UCSD, Pediatric and Adolescent Dermatology
San Diego, California, United States, 92123
United States, Colorado
Denver Children's Hospital
Aurora, Colorado, United States, 80045
United States, Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611
United States, Virginia
Virginia Clinical Research, Inc
Norfolk, Virginia, United States, 23507
Landeskrankenhaus Salzburg-Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Salzburg, Austria
Canada, Ontario
Toronto Regional Wound Healing Clinic
Mississauga, Ontario, Canada
Canada, Quebec
University of Montreal
Montreal, Quebec, Canada
Hôpital Necker-Enfants Malades
Paris, Ile-De France, France
University of Freiburg (Studiensekretariat Hautklinik Universitätsklinikum Freiburg - Hautklinik)
Freiburg, Baden-Wuerttemberg, Germany
Warszawki Uniwersytet Medyczny Katedra I Klinika Dermatologiczna
Warszawa, Mazowieckie, Poland
Hospital CUF Descobertas
Lisboa, Portugal
Hospital Universitario La Paz
Madrid, Spain
Sponsors and Collaborators
Shire Regenerative Medicine, Inc.
Layout table for investigator information
Principal Investigator: Alan Arbuckle, MD, FAAD, FAAP H&E Enterprises
Layout table for additonal information
Responsible Party: Shire Regenerative Medicine, Inc. Identifier: NCT01749306    
Other Study ID Numbers: EB01-ABH001
2012-001815-21 ( EudraCT Number )
First Posted: December 13, 2012    Key Record Dates
Last Update Posted: November 21, 2013
Last Verified: November 2013
Keywords provided by Shire Regenerative Medicine, Inc.:
epidermolysis bullosa, chronic wound, wound healing, dermal repair, fibroblasts, Dermagraft
Additional relevant MeSH terms:
Layout table for MeSH terms
Epidermolysis Bullosa
Skin Abnormalities
Congenital Abnormalities
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Skin Diseases, Vesiculobullous